SK Biopharmaceuticals Co., Ltd., operating within the Healthcare sector and specifically the Biotechnology industry, currently holds a market capitalization of 5.97 Trillion KRW. The stock is trading at KRW76,300.00, having seen a 4.09% increase in the last 24 hours but a modest 0.39% gain over the past seven days. As a growth-oriented biotechnology firm, it currently offers no dividend yield, and its P/E ratio is not available for assessment.

Our technical scoring system assigns a total score of -2, leading to a 'Sell' rating for SK Biopharmaceuticals. The primary driver for this bearish outlook is the long-term trend, as the current price of KRW76,300.00 remains significantly below its 200-day Simple Moving Average (SMA) of KRW95,667.00, indicating a clear downtrend. The ADX reading below 25 suggests a lack of strong trend momentum, while the RSI 14 at 49.75 points to a neutral momentum, neither overbought nor oversold. On a more positive note, the MACD histogram is positive at 197.52, suggesting some short-term bullish momentum, and the On-Balance Volume (OBV) is above its 5-day SMA, indicating recent accumulation. However, these short-term positives are outweighed by the dominant long-term bearish trend.

From a fundamental and earnings perspective, SK Biopharmaceuticals reported an impressive last EPS of 1343.0, accompanied by an extraordinary earnings surprise of 17920.0%. This indicates a significant outperformance relative to analyst expectations, which is a strong positive signal for the company's operational efficiency and growth potential. However, the next earnings report is not due until 05/11/2026, leaving a long period without fresh fundamental updates. While the exceptional earnings surprise provides a strong underlying positive, the current technical indicators, particularly the long-term price trend, suggest caution for investors in the short to medium term.